α-tubulin

Tubulin inhibitor 32 is an orally active novel microtubule inhibitor with antiproliferative and antitumor activity, inhibits microtubule polymerization, induces apoptosis and cell cycle arrest in G2/M phase.

Tubulin polymerization-IN-43 is an inhibitor of tubulin polymerisation.Tubulin polymerization-IN-43 has multiple effects, disrupting the cellular microtubule network by targeting the colchicine locus and promoting cell cycle arrest and apoptosis in leukaemia cells. Tubulin polymerisation-IN-43 has multiple effects, promoting leukaemia cell cycle arrest in G2/M phase and apoptosis by targeting Colchicine sites to disrupt the cellular microtubule network.

Tubulin inhibitor 24 is a potent compound that inhibits tubulin polymerization.

Tubulin inhibitor 35 (Tubulin IN 35) is a potent dual inhibitor of topoisomerase I and microtubule protein polymerization with antitumor activity, inhibits migration and invasion of MGC-803 and RKO cell lines, interrupts the cell cycle and induces apoptosis.

Tubulin inhibitor 6 (iHAP1) is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines.

Tubulin polymerization-IN-57 (compound 5a), an α-naphthoxy-substituted carbendazim derivative, functions as a tubulin inhibitor. It effectively induces mitotic arrest and suppresses the proliferation of cancer cells [1].

Anti-α-Tubulin Antibody, AF555 conjugate, is a mouse-derived monoclonal antibody conjugated with the red fluorescent dye Alexa Fluor 555, designed for the specific detection of tubulin (Ex Em: 554 567 nm) [1].

Tubulin Inhibitor 36 (Compound 10) serves as a potent novel inhibitor of tubulin polymerization, which consequently induces apoptosis in glioblastoma cells, reflected by an IC50 value of 1.5±0.1 μM. Exhibiting significant anti-mitotic activity, this compound demonstrates anti-tumor potential, particularly useful in glioblastoma multiforme (GBM) research [1].

Tubulin Inhibitor 38 (Compound 14), a tetrazole-based agent, demonstrates significant antiproliferative effects by inducing mitotic arrest and blocking the cell cycle at the G2/M phase, ultimately triggering apoptosis. Administered at 100 nM for 24 hours, it shows considerable cytotoxicity and selectivity within HeLa, MCF7, and U87 MG cell lines [1].

Tubulin Inhibitor 37 (Compound 12) effectively impedes tubulin aggregation (IC50 = 1.3 µM) and demonstrates antiproliferative activity against human tumor cell lines, showing promise for cancer research [1].

Tubulin polymerization-IN-45, a tubulin-targeting agent, inhibits tubulin polymerization by binding to tubulin's colchicine site, inducing apoptotic cell death in hepatocellular cancer (HCC) cells [1].

Tubulin polymerization-IN-46 (compound 9q) is a microtubule tubulin inhibitor that obstructs tubulin polymerization, triggers apoptosis, and arrests MCF-7 breast cancer cells in the G2 M phase, demonstrating potent anti-proliferative activity with an IC50 of 10 nM [1].

Tubulin polymerization-IN-9, a potent inhibitor of tubulin (IC50: 1.82 μM), arrests the cell cycle of K562 cells in the G2 M phase, induces apoptosis and mitochondrial depolarization, and exhibits strong anti-vascular and anti-tumor effects.

Tubulin inhibitor 14 is a potent inhibitor of NQO2 (quinone oxidoreductase 2) with an IC50 of 1.0 μM, which also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. As a microtubule destabilizer, Tubulin inhibitor 14 has potential tumor-selective, anti-angiogenic, and vascular-destructive properties [1].

IDO Tubulin-IN-2 (HT2) is a potent inhibitor of TDO and tubulin, showing significant efficacy against cancer cell lines U87, HepG2, A549, HCT-116, and LO2, with respective IC50 values of 0.43, 0.036, 0.041, 0.095, and 1.04 μM. Additionally, IDO Tubulin-IN-2 markedly enhances antitumor activity [1].

Tubulin polymerization-IN-29 is a potent inhibitor of microtubule protein polymerization and shows potent anti-proliferative effects.Tubulin polymerization-IN-29 induces cell cycle arrest in HeLa cells at G2/M phase.

Tubulin Inhibitor 33 is a dose-dependent inhibitor of tubulin polymerization, exhibiting an IC50 value of 9.05 μM. This compound demonstrates antitumor activity and induces apoptosis, making it useful for antitumor research [1].

Tubulin polymerization-IN-26 (compound 12h) is a chemical compound that inhibits the polymerization of microtubulin by binding to the colchicine binding site, with an IC50 value of 4.64 μM. It can induce apoptosis and inhibit cell metastasis, making it a valuable compound for researching lung cancer [1].

Tubulin polymerization-IN-35 is [1,2] an inhibitor of oxazolylisoindole microtubulin polymerization that acts highly selectively on the marginal zone lymphoma VL51 cell line.

Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor that impedes cancer cell proliferation, making it a valuable tool for researching cancers, including lymphoma.

Tubulin inhibitor 1 is an inhibitor of tubulin, inhibits tubulin polymerization, with potent anti-tumor activity, induces cellular apoptosis causes and cellular mitotic arrest in the G2/M phase.

Tubulin polymerization-IN-14 (Compound 20a) is a tubulin polymerization inhibitor (IC50 = 3.15 μM) that demonstrates strong anti-vascular and anticancer activities, including inducing cancer cell apoptosis [1].

Tubulin polymerization-IN-39, a tubulin polymerization inhibitor with an IC50 of 4.9 μM, targets the colchicine-binding site to hinder tubulin polymerization. This compound effectively suppresses cancer cell proliferation.

Tubulin inhibitor 41 (Compd D19) is a promising lead compound for glioblastoma treatment, known for its ability to penetrate the blood-brain barrier (BBB). It functions as a tubulin inhibitor, inducing G2 M phase arrest, leading to cell apoptosis, and inhibiting the migration of U87 cells [1].

Tubulin polymerization-IN-61 (Compound 9a), a tubulin polymerization inhibitor, disrupts the microtubule skeleton, arrests the cell cycle at the G2 M phase, induces Apoptosis, and impedes cancer cell migration and colony formation. This compound demonstrates antitumor efficacy in vivo within the 4T1 xenograft model [1].

Tubulin polymerization-IN-63 (compound 6) is an inhibitor of tubulin polymerization. It exhibits an IC50 value of 0.29 μM against MES-SA cells, making it suitable for use in cancer research.

Tubulin inhibitor 43 exhibits significant antitumor activity by impeding the proliferation and growth of cancer cells through the inhibition of β-microtubulin activity, ultimately inducing apoptosis [1].

PROTAC tubulin-Degrader-1 (Compound W13) functions as an inhibitor of PROTAC tubulin and exhibits anti-tumor activity against human lung cancer.

Tubulin Polymerization-IN-51 (compound 7u) serves as a tubulin polymerization inhibitor, exhibiting an IC50 range of 2.55 - 17.89μM against SK-Mel-28 cells, and is applicable in cancer research [1].

Tubulin HDAC-IN-2 (Compound II-19k) is a dual inhibitor of Tubulin and HDAC, with IC50 values of 0.403 μM for HDAC1, 0.591 μM for HDAC2, 3.552 μM for HDAC3, and 0.459 μM for HDAC6. The compound induces G2 phase cell cycle arrest, promotes apoptosis, hampers hematoma and solid tumor cell proliferation, diminishes tumor metastasis, and inhibits tumor growth in a liver tumor allograft mouse model [1].

Tubulin Inhibitor 11 is a potent, orally active agent that inhibits tubulin by targeting the Colchicine binding site. It impedes tubulin polymerization, leading to mitotic blockade and apoptosis.

Tubulin polymerization-IN-6 (compound 5f) is a potent tubulin polymerization inhibitor with an IC50 of 1.09 μM. It inhibits cell migration and tube formation, exhibits anti-angiogenic properties, and effectively hinders tumor growth in HT29 xenograft Balb c nude mice [1].

Tubulin Inhibitor 27 (DYT-1), a compound that inhibits tubulin polymerization with an IC50 of 25.6 μM, exhibits anti-angiogenesis and antitumor activities [1].

Tubulin polymerization-IN-21 is an inhibitor of microtubulin polymerization that disrupts cell integrity and affects glucose metabolism, and has anticancer effects.

Tubulin inhibitor 29 (compound 3c) is a potent tubulin inhibitor that disrupts tubulin assembly by binding at the colchicine site (IC50 = 1.2 μM), and exhibits antiproliferative effects on MCF-7 cells with an IC50 value of 7.5 μM. [1].

Tubulin polymerization-IN-42 (compound 10j), an indole-substituted furanone, inhibits tubulin polymerization and exhibits anti-cancer properties [1].

Tubulin polymerization-IN-52 (compound SC23) effectively inhibits tubulin polymerization with an IC50 value of 2.9 μM [1].

Tubulin inhibitor 20 (compound 1) exhibits significant potential for cancer research as a potent tubulin inhibitor [1].

Tubulin Polymerization-IN-2 is a powerful anticancer agent that targets β-tubulin, exhibiting an IC 50 of 0.92 μM. It demonstrates promising efficacy against a range of cancer cell lines including leukemia, non-small cell lung, renal, prostate, and breast cancers [1].

Tubulin polymerization-IN-25 is a selective, dual tubulin polymerization (IC50: 1.11 μM) and farnesyl transferase (FTase) (IC50: 0.39 μM) inhibitor. polymerization-IN-25 exhibits cytotoxicity against cancer cells and blocks cell proliferation.

Tubulin polymerization-IN-53 (compound 4b) inhibits β-tubulin polymerization, arrests the cell cycle at the G2 M stage, and demonstrates antiproliferative efficacy against the MDA-MB-231 cell line, with an IC50 value of 3.24 μM [1].

Tubulin polymerization-IN-31 (Compound 4c) is an inhibitor of tubulin polymerization with an IC50 value of 3.64 μM [1], exhibiting antitumor activity and inducing apoptosis in cancer cells.

Tubulin polymerization-IN-8 (compound IIc) is a potent inhibitor of tubulin polymerization, inducing concentration-dependent cell cycle arrest at the G2 M phase in HCT116 tumor cells and significantly inhibiting tubulin polymerization with an IC50 of 12.7 μM, showing potential for cancer research [1].

Tubulin inhibitor 19 (compound 9b) is a potent indole chalcone compound exhibiting strong tubulin inhibitory activity, making it valuable for cancer research [1].

Tubulin polymerization-IN-10 is a highly potent inhibitor of tubulin polymerization with an IC50 value of 4.25±0.75 μM, exhibiting significant anti-tumor properties [1].

Tubulin polymerization-IN-33, an [1,2] inhibitor of oxazoloisoindole microtubulin polymerization, is an effective anti-proliferative agent for NCI series cancer cells.

Tubulin inhibitor 17 (Compound 3b) is an inhibitor of tubulin polymerization (IC50 = 12.38 µM) that exhibits anticancer activities and induces cell apoptosis[1].

Tubulin inhibitor 23 is a potent tubulin inhibitor (IC50: 4.8 μM) that exhibits antiangiogenic effects in a dose-dependent manner and induces apoptosis. This compound shows potential for leukemia research.